{"product_id":"pbla-vrio-analysis","title":"Panbela Therapeutics, Inc. (PBLA): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Panbela Therapeutics, Inc. (PBLA)'s enduring success with this laser-focused VRIO analysis. We distill the complex interplay of its Value, Rarity, Inimitability, and Organization to pinpoint the exact resources creating a true, sustainable competitive advantage in the market. Don't just guess at their edge - read the summary below to see precisely what makes Panbela Therapeutics, Inc. (PBLA) formidable and where its next opportunity lies.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePanbela Therapeutics, Inc. (PBLA) - VRIO Analysis: Ivospemin (SBP-101) Clinical Efficacy Signal\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core asset of Panbela Therapeutics, Inc. (PBLA), the potential of Ivospemin (SBP-101) in metastatic pancreatic cancer (mPDAC). The whole story hinges on the upcoming data from the ASPIRE trial. Here’s the quick math: the drug showed a median Overall Survival (OS) of \u003cstrong\u003e14.6 months\u003c\/strong\u003e and an Objective Response Rate (ORR) of \u003cstrong\u003e48%\u003c\/strong\u003e in prior Phase 1b studies when added to standard chemotherapy. That’s the value proposition we are assessing right now.\u003c\/p\u003e\n\n\u003ch3\u003eIvospemin (SBP-101) Clinical Efficacy Signal\u003c\/h3\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: The Demonstrated Signal\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe demonstrated signal in metastatic pancreatic cancer (mPDAC) patients - a median Overall Survival (OS) of \u003cstrong\u003e14.6 months\u003c\/strong\u003e and an Objective Response Rate (ORR) of \u003cstrong\u003e48%\u003c\/strong\u003e when added to standard-of-care - provides a strong basis for future value creation and partnership discussions. To be fair, these numbers come from earlier Phase 1b\/2 data, but they are the foundation. The ASPIRE Phase III trial, aiming for full enrollment of about \u003cstrong\u003e600 patients\u003c\/strong\u003e by Q1 2025, is designed to validate this potential in a registration-enabling study. The third independent safety review on \u003cstrong\u003e395 patients\u003c\/strong\u003e recommended continuation without modification, which is a good sign for the trial's integrity. That interim analysis is what everyone is waiting for, anticipated in Q1 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Outperforming the Baseline\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA high ORR and OS benefit in a difficult-to-treat cancer like mPDAC, exceeding typical historical benchmarks for the standard-of-care backbone, is rare for an early-stage asset. Honestly, the prognosis for mPDAC patients remains poor, with median OS still often cited as less than \u003cstrong\u003e12 months\u003c\/strong\u003e despite recent regimen approvals showing only incremental gains, like a \u003cstrong\u003e1.9 month\u003c\/strong\u003e benefit for NALIRIFOX. Hitting \u003cstrong\u003e48%\u003c\/strong\u003e ORR and \u003cstrong\u003e14.6 months\u003c\/strong\u003e OS in that context is definitely noteworthy, but it’s based on a smaller, earlier data set.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Mechanism vs. Data\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe specific clinical data set and the drug’s unique mechanism are hard to copy quickly, but the underlying polyamine pathway is known science. Ivospemin is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI). Competitors can study the pathway, but replicating the exact efficacy signal seen in the Phase 1b\/2 trial, especially the long-term survival seen in a couple of patients, is tough. Still, if the ASPIRE readout is positive, other companies with pathway knowledge could pivot faster than they could have before the data drops.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Cash Constraints Loom Large\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company is organized to exploit this by advancing the Phase III ASPIRE trial, though cash constraints defintely test this organization. As of March 31, 2024, Panbela Therapeutics reported a net loss of \u003cstrong\u003e$7.1 million\u003c\/strong\u003e and a cash balance of only about \u003cstrong\u003e$260,000\u003c\/strong\u003e. Current liabilities were \u003cstrong\u003e$10.5 million\u003c\/strong\u003e against current assets of just \u003cstrong\u003e$1.8 million\u003c\/strong\u003e at that time. Research and development expenses were high, around \u003cstrong\u003e$7.0 million\u003c\/strong\u003e in Q2 2024 alone, driven by ASPIRE enrollment. You need to see a capital raise or a partnership to fund operations past the Q1 2025 readout. That cash runway is the biggest organizational hurdle right now.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Data Maturation Dependency\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary. The advantage rests on the data maturing and being validated in the final ASPIRE readout, which was anticipated in Q1 2025. If the Phase III data confirms the Phase 1b signal, the advantage becomes much stronger, potentially moving toward sustained. If it misses, the advantage evaporates instantly. It’s a binary event right now.\u003c\/p\u003e\n\n\u003cp\u003eHere is a quick scoring of the current state based on the existing data:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eVRIO Dimension\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eAssessment\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eScore (1-4)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eImplication\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eHigh potential OS\/ORR signal in mPDAC.\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eBasis for partnership\/licensing discussions.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eExceeds historical standard-of-care benchmarks.\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eAttracts attention, but not yet validated in Phase III.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eMechanism known, but specific data set is unique.\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eCan be imitated over time if data is positive.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eOrganized for trial, but severely cash-constrained.\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eRisk of not reaching the critical Q1 2025 inflection point.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe key factors driving the near-term competitive position are:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAnticipated ASPIRE interim analysis in \u003cstrong\u003eQ1 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNeed for significant capital to bridge to the readout.\u003c\/li\u003e\n\u003cli\u003ePhase 1b OS of \u003cstrong\u003e14.6 months\u003c\/strong\u003e vs. mPDAC baseline \u0026lt; \u003cstrong\u003e12 months\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash balance reported near zero as of \u003cstrong\u003eMarch 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePanbela Therapeutics, Inc. (PBLA) - VRIO Analysis: Proprietary Polyamine Metabolic Inhibitor (PMI) Technology Platform\n\u003c\/h2\u003e\n\n\u003cp\u003eProprietary Polyamine Metabolic Inhibitor (PMI) Technology Platform\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThis core science allows Panbela Therapeutics to target a fundamental metabolic pathway critical in multiple tumor types, giving them a platform for several pipeline assets beyond just SBP-101.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eWhile polyamine research isn't new, their specific proprietary analogue design and its application across multiple indications (pancreatic cancer, NSCLC, FAP) is somewhat unique in the current clinical landscape.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe core scientific concept is imitable, but the specific compounds and their optimized delivery methods are protected by IP. A New Patent was issued in the US and Canada for Claims of a Fixed Dose Combination of Eflornithine and Sulindac.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe scientific team, including advisors, is structured to explore new indications, as seen with the Phase I study in STK11 mutant NSCLC.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase I dose-escalation study of CPP-1X-S in STK11 mutant NSCLC initiated.\u003c\/li\u003e\n\u003cli\u003eData from the STK11 mutant NSCLC Phase I trial expected by mid-2025.\u003c\/li\u003e\n\u003cli\u003eASPIRE trial (SBP-101 in 1st-line mPDAC) anticipates complete enrollment of approximately 600 patients by Q1 2025.\u003c\/li\u003e\n\u003cli\u003eASPIRE trial interim survival analysis expected Q1 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eTemporary. It’s a strong platform, but sustained advantage requires continuous, successful clinical validation across those multiple indications.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset\/Indication\u003c\/td\u003e\n\u003ctd\u003eStudy Phase\/Design\u003c\/td\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIvospemin (SBP-101) in mPDAC (Combo with Gem\/Nab-P)\u003c\/td\u003e\n\u003ctd\u003ePhase 1a\/1b (N=29 evaluable)\u003c\/td\u003e\n\u003ctd\u003eMedian Overall Survival (OS) Final\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14.6 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIvospemin (SBP-101) in mPDAC (Combo with Gem\/Nab-P)\u003c\/td\u003e\n\u003ctd\u003ePhase 1a\/1b (N=29 evaluable)\u003c\/td\u003e\n\u003ctd\u003eObjective Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e48%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIvospemin (SBP-101) in mPDAC (Combo with Gem\/Nab-P)\u003c\/td\u003e\n\u003ctd\u003ePhase 1a\/1b (N=29 evaluable)\u003c\/td\u003e\n\u003ctd\u003eMedian Progression Free Survival (PFS) Final\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6.5 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIvospemin (SBP-101) in mPDAC\u003c\/td\u003e\n\u003ctd\u003ePhase 1 Cohort 2 (N=7)\u003c\/td\u003e\n\u003ctd\u003eObjective Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e71%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIvospemin (SBP-101) in mPDAC\u003c\/td\u003e\n\u003ctd\u003ePhase 1 Cohort 2 (N=7)\u003c\/td\u003e\n\u003ctd\u003eMedian Overall Survival (OS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10.3 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPP-1X + Sulindac in FAP (Lower GI Anatomy)\u003c\/td\u003e\n\u003ctd\u003ePhase III Combination vs Monotherapy\u003c\/td\u003e\n\u003ctd\u003eRisk Reduction for Need for LGI Surgery (up to 48 months)\u003c\/td\u003e\n\u003ctd\u003eApproaching \u003cstrong\u003e100%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFinancial Data (as of September 30, 2024, Q3 2024):\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet loss in the quarter: approximately \u003cstrong\u003e$7.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet loss per diluted share: \u003cstrong\u003e$1.48\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal cash: \u003cstrong\u003e$142,000\u003c\/strong\u003e (prior to Nant Capital investment).\u003c\/li\u003e\n\u003cli\u003eTotal current assets: \u003cstrong\u003e$5.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCurrent liabilities: \u003cstrong\u003e$20.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNotes payable, plus accrued interest: approximately \u003cstrong\u003e$6.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFinancing commitment secured in Q3\/Q4 2024: Up to \u003cstrong\u003e$12.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePanbela Therapeutics, Inc. (PBLA) - VRIO Analysis: SBP-101 Novel Manufacturing Process Patent\n\u003c\/h2\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eU.S. Patent US \u003cstrong\u003e11,098,005\u003c\/strong\u003e claims a novel process for SBP-101 production, reducing synthetic steps from \u003cstrong\u003eseventeen\u003c\/strong\u003e down to \u003cstrong\u003esix\u003c\/strong\u003e. The initial literature preparation involved a \u003cstrong\u003e15-step\u003c\/strong\u003e process. This process development was a collaboration with Syngene International Ltd. The patented process enables a scalable, efficient, and cost-effective manufacturing process for future commercialization. In one Phase 1b cohort, SBP-\u003cstrong\u003e101\u003c\/strong\u003e + Gemcitabine\/Nab-paclitaxel showed a median Overall Survival of \u003cstrong\u003e14.6 months\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePrevious Synthesis\u003c\/th\u003e\n\u003cth\u003ePatented Process (US 11,098,005)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSynthetic Steps\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Exploration Steps\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent Protection End Year\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2039\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eA patent streamlining a complex drug synthesis process by a factor of over \u003cstrong\u003e2.8x\u003c\/strong\u003e (from 17 to 6 steps) is rare for a small company. The collaboration with Syngene International Ltd. resulted in this optimization, with the partnership extended through \u003cstrong\u003e2030\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eCompetitors are legally barred from imitating this specific, patented, cost-saving process until the patent expires in \u003cstrong\u003e2039\u003c\/strong\u003e. The initial process involved a chiral purity check showing \u003cstrong\u003e85%\u003c\/strong\u003e purity, which Syngene improved to \u003cstrong\u003e98%\u003c\/strong\u003e with a 17-step modification before the 6-step invention.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReduced lead time for manufacturing product.\u003c\/li\u003e\n\u003cli\u003eQuicker access to drug supply facilitating expansion into additional indications.\u003c\/li\u003e\n\u003cli\u003eEnables a scalable, efficient, and cost-effective manufacturing process.\u003c\/li\u003e\n\u003cli\u003ePotential to reduce production costs and improve overall competitiveness.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe execution of this value-adding manufacturing optimization through the collaboration with Syngene International Ltd. demonstrates organizational capability. Financial context for the organization includes: Panbela closed a public offering of \u003cstrong\u003e$9.0 million\u003c\/strong\u003e. For Q1 2024, General and administrative expenses were approximately \u003cstrong\u003e$1.2 million\u003c\/strong\u003e, while Research and development expenses were about \u003cstrong\u003e$5.5 million\u003c\/strong\u003e, resulting in a net loss of approximately \u003cstrong\u003e$7.1 million\u003c\/strong\u003e, or \u003cstrong\u003e$2.28 per diluted share\u003c\/strong\u003e. Total cash as of March 31, 2024, was \u003cstrong\u003e$262,000\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e. The advantage is legally protected via patent coverage extending to \u003cstrong\u003e2039\u003c\/strong\u003e in the U.S. and other jurisdictions, providing a clear, cost-saving barrier to entry for competitors seeking to manufacture SBP-101 via this optimized route.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePanbela Therapeutics, Inc. (PBLA) - VRIO Analysis: ASPIRE Trial Momentum and Data Cadence\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ongoing Phase III ASPIRE trial is the single most important near-term value driver, with interim analysis expected in \u003cstrong\u003eQ1 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e A Phase III trial in mPDAC is a rare asset for a company of this size. The lower-than-anticipated event rate is a positive sign, suggesting patients are living longer.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The trial itself, the patient population, and the specific endpoints are unique to Panbela Therapeutics.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The clinical operations team is organized to manage this large, ongoing trial. Resource allocation is tested by the delay in data analysis.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The advantage is entirely dependent on the positive outcome of the data analysis.\u003c\/p\u003e\n\u003cp\u003eKey statistical and financial metrics related to the ASPIRE trial and recent financial reporting:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eASPIRE Interim Analysis Target\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ1 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExpected Timing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASPIRE Enrollment Completion Target\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ2 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAnticipated Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASPIRE Safety Review Patient Count\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e395\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncluded in Third DSMB Review\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2024 Research \u0026amp; Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.0 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarter Ended June 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2024 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.1 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarter Ended June 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Cash\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$59,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.8 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive OS Benefit (NALIRIFOX)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.9\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMonths Median Survival Benefit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eTrial progression milestones include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eASPIRE trial surpassed \u003cstrong\u003e50%\u003c\/strong\u003e enrollment as of January (Q4 2023 context).\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ1 2024 Research and development expenses were approximately \u003cstrong\u003e$5.5 Million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ1 2024 Net Loss was approximately \u003cstrong\u003e$7.1 Million\u003c\/strong\u003e, or \u003cstrong\u003e$2.28 per diluted share\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eTotal cash as of March 31, 2024, was \u003cstrong\u003e$262,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePanbela Therapeutics, Inc. (PBLA) - VRIO Analysis: Flynpovi (CPP-1X\/Sulindac) Combination Asset\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eFlynpovi (CPP-1X\/Sulindac) Combination Asset Metrics\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Efficacy (FAP Trial)\u003c\/td\u003e\n\u003ctd\u003ePrevention of pre-cancerous sporadic adenomas vs. placebo\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt; 90%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Efficacy (FAP Lower GI Anatomy)\u003c\/td\u003e\n\u003ctd\u003eStatistically significant benefit vs. single agents (p-value)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003ep≤0.02\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Efficacy (FAP Lower GI Anatomy)\u003c\/td\u003e\n\u003ctd\u003eDelay in surgical events up to\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003efour years\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition Contingent Payments\u003c\/td\u003e\n\u003ctd\u003eMaximum future milestone\/royalty payments to CPP stockholders\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$60 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombined Pipeline Market Opportunity\u003c\/td\u003e\n\u003ctd\u003eEstimated aggregate market opportunity for initial focus areas\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2024 Financials\u003c\/td\u003e\n\u003ctd\u003eNet Loss for the quarter\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2024 Financials\u003c\/td\u003e\n\u003ctd\u003eDiluted Loss Per Share for the quarter\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.47\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBalance Sheet (June 30, 2024)\u003c\/td\u003e\n\u003ctd\u003eTotal Cash\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$59,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBalance Sheet (June 30, 2024)\u003c\/td\u003e\n\u003ctd\u003eCurrent Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBalance Sheet (June 30, 2024)\u003c\/td\u003e\n\u003ctd\u003eNotes Payable (CPP Acquisition related)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eDual mechanism targeting polyamine synthesis inhibition and export\/catabolism. Pipeline diversification away from SBP-101. Targeting colorectal cancer prevention and FAP. In a Phase 3 clinical trial in patients with sporadic large bowel polyps, the combination prevented \u003cstrong\u003e\u0026gt; 90%\u003c\/strong\u003e subsequent pre-cancerous sporadic adenomas versus placebo. For FAP patients with lower GI anatomy, Flynpovi showed statistically significant benefit compared to both single agents ($\\text{p}\\le\\mathbf{0.02}$) in delaying surgical events in the lower GI for up to \u003cstrong\u003efour years\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nCombination therapy with a dual-action mechanism targeting polyamine pathways.\n\u003c\/li\u003e\n\u003cli\u003e\nNo currently approved drug therapies exist for the treatment of FAP.\n\u003c\/li\u003e\n\u003cli\u003e\nThe combined entity's initial focus areas represented an estimated aggregate \u003cstrong\u003e$5 billion\u003c\/strong\u003e market opportunity.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eSpecific combination and development pathway are proprietary. The acquisition included contingent payments totaling a maximum of \u003cstrong\u003e$60 million\u003c\/strong\u003e from milestone and royalty payments associated with potential approval and commercialization.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nAcquisition of Cancer Prevention Pharmaceuticals, Inc. closed on June 15, 2022.\n\u003c\/li\u003e\n\u003cli\u003e\nThe combined entity will be led by Jennifer Simpson, Chief Executive Officer of Panbela.\n\u003c\/li\u003e\n\u003cli\u003e\nPanbela regained the North American rights to develop and commercialize Flynpovi in April 2023.\n\u003c\/li\u003e\n\u003cli\u003e\nNotes payable, plus accrued interest, on the balance sheet resulting from the acquisition totaled approximately \u003cstrong\u003e$4.3 million\u003c\/strong\u003e as of June 30, 2024.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eTemporary. The asset is a hedge against SBP-101 progression. The company reported total cash of \u003cstrong\u003e$59,000\u003c\/strong\u003e as of June 30, 2024, with current liabilities at \u003cstrong\u003e$16.8 million\u003c\/strong\u003e. The stock price decreased by \u003cstrong\u003e-96.54%\u003c\/strong\u003e in the last 52 weeks.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePanbela Therapeutics, Inc. (PBLA) - VRIO Analysis: Executive Retention and Alignment Incentives\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The January 2025 retention bonuses for key executives, including CEO Jennifer K. Simpson and CFO Susan Horvath, align their immediate interests with achieving a critical financial milestone - an unrestricted cash balance exceeding \u003cstrong\u003e$10,000,000\u003c\/strong\u003e - or a change in control by December 31, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The specific structure tying retention to a significant cash hurdle or an exit event is a tailored, though not entirely unique, governance tool for pre-commercial biotechs.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The specific bonus amounts (\u003cstrong\u003e$186,000\u003c\/strong\u003e for the CEO, \u003cstrong\u003e$105,000\u003c\/strong\u003e for the CFO) and conditions are internal and not easily copied.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The Compensation Committee’s action demonstrates an organization focused on retaining critical leadership through a known liquidity crunch period.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This is a short-term organizational fix to bridge a critical period.\u003c\/p\u003e\n\u003cp\u003eExecutive Retention Incentive Details:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eExecutive\u003c\/th\u003e\n\u003cth\u003e2025 Retention Bonus Amount\u003c\/th\u003e\n\u003cth\u003ePrimary Financial Hurdle\u003c\/th\u003e\n\u003cth\u003eVesting Deadline\/Trigger\u003c\/th\u003e\n\u003cth\u003e2024 Retention Bonus Amount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEO Jennifer K. Simpson\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$186,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUnrestricted cash balance exceeding \u003cstrong\u003e$10,000,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2025, or Change in Control\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$54,281\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCFO Susan Horvath\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$105,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUnrestricted cash balance exceeding \u003cstrong\u003e$10,000,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2025, or Change in Control\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$34,299\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOrganizational Focus Metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTarget Unrestricted Cash Balance: \u003cstrong\u003e$10,000,000\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eRetention Agreement Approval Date: January 29, 2025\u003c\/li\u003e\n\u003cli\u003eLatest Reported Market Capitalization: \u003cstrong\u003e$1.7M\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCFO 2023 Performance Payout: \u003cstrong\u003e$119,394\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eRetention Conditions:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eContinued employment through the earliest of:\n\u003cul\u003e\n\u003cli\u003eDate Company achieves unrestricted cash balance in excess of \u003cstrong\u003e$10,000,000\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eDecember 31, 2025\u003c\/li\u003e\n\u003cli\u003eDate Company terminates employment without cause before December 31, 2025\u003c\/li\u003e\n\u003cli\u003eDate a change in control is completed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePanbela Therapeutics, Inc. (PBLA) - VRIO Analysis: Strategic Investor Financing Commitment\n\u003c\/h2\u003e\n\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe secured commitment of up to \u003cstrong\u003e$12.0 million\u003c\/strong\u003e from Nant Capital provides a crucial lifeline, helping to fund operations past the Q3 2024 cash position of only \u003cstrong\u003e$142,000\u003c\/strong\u003e and manage liabilities of \u003cstrong\u003e$20.1 million\u003c\/strong\u003e as of September 30, 2024.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eSecuring a significant strategic financing commitment when current liabilities of \u003cstrong\u003e$20.1 million\u003c\/strong\u003e far outweigh current assets of \u003cstrong\u003e$5.2 million\u003c\/strong\u003e is a rare feat, showing strong investor confidence in the underlying science, including ivospemin data showing a median overall survival (OS) of \u003cstrong\u003e14.6 months\u003c\/strong\u003e and an objective response rate (ORR) of \u003cstrong\u003e48%\u003c\/strong\u003e in studies.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eThe specific terms and relationship with Nant Capital are unique to Panbela Therapeutics, involving convertible promissory notes with a first tranche funded of \u003cstrong\u003e$2.85 million\u003c\/strong\u003e on October 22, 2024, and a second tranche expected of \u003cstrong\u003e$9.15 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe finance function successfully negotiated this commitment, which is vital for continuing R\u0026amp;D expenses of approximately \u003cstrong\u003e$6.1 million\u003c\/strong\u003e per quarter (Q3 2024 actual) and managing cash used in operations of approximately \u003cstrong\u003e$12.5 million\u003c\/strong\u003e for the nine months ended September 30, 2024.\u003c\/p\u003e\n\n\u003cp\u003eKey Financial Metrics Supporting Assessment:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount (as of Q3 2024 End)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNant Capital Commitment\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$12.0 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash on Hand (Pre-Funding)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$142,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2024 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2024 R\u0026amp;D Expense\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$6.1 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2024 G\u0026amp;A Expense\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$1.1 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary. This funding bridges the gap, providing runway past the \u003cstrong\u003e$142,000\u003c\/strong\u003e cash position, but the advantage fades as the cash is spent without a major clinical or commercial milestone.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe loan notes mature in six months.\u003c\/li\u003e\n\u003cli\u003eThe loan bears interest at \u003cstrong\u003e8%\u003c\/strong\u003e plus the Monthly SOFR Rate.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePanbela Therapeutics, Inc. (PBLA) - VRIO Analysis: Niche Focus on Pancreatic Cancer and Related Diseases\n\u003c\/h2\u003e\n\n\u003cp\u003eNiche Focus on Pancreatic Cancer and Related Diseases\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e By concentrating development efforts on high-unmet-need areas like pancreatic cancer and high-risk myelodysplastic syndromes (HR-MDS), Panbela Therapeutics targets indications where even incremental survival benefits command significant market attention and premium pricing potential.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Year\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSBP-101 Median Overall Survival (mPDAC)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14.6 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eClinical Study Data in Metastatic Pancreatic Cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSBP-101 Objective Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e48%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eClinical Study Data in Metastatic Pancreatic Cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePancreatic Cancer Market Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.8 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023 Valuation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePancreatic Cancer Market Forecast CAGR\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15.85%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eForecast period 2024-2032\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASPIRE Trial Enrollment Target\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e~600\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eAnticipated by Q1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e While many companies target oncology, the deep, sustained focus on the polyamine pathway specifically within pancreatic cancer creates a specialized knowledge base.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLead investigational compound, SBP-101 (Ivospemin), is a proprietary stabilized spermine analogue designed to inhibit polyamine metabolism.\u003c\/li\u003e\n\u003cli\u003eThe company's pipeline is centered on SBP-101 in combination with standard-of-care regimens for high-mortality indications.\u003c\/li\u003e\n\u003cli\u003eExocrine pancreatic cancers accounted for a \u003cstrong\u003e63.23%\u003c\/strong\u003e market share in 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Competitors would need to replicate years of focused research and clinical trial design in this specific niche.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSBP-101 efficacy signals (OS of \u003cstrong\u003e14.6 months\u003c\/strong\u003e, ORR of \u003cstrong\u003e48%\u003c\/strong\u003e) suggest potential complementary activity with the existing FDA-approved standard chemotherapy regimen of gemcitabine + nab-paclitaxel.\u003c\/li\u003e\n\u003cli\u003eThe ASPIRE trial, evaluating SBP-101 in metastatic pancreatic ductal adenocarcinoma (mPDAC), has surpassed \u003cstrong\u003e50%\u003c\/strong\u003e enrollment.\u003c\/li\u003e\n\u003cli\u003eThe company reported a net loss of approximately \u003cstrong\u003e$7.2 million\u003c\/strong\u003e for the Third Quarter ended September 30, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company’s entire structure, from the CEO’s background to the pipeline focus, is aligned around this therapeutic area.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePresident \u0026amp; CEO: Jennifer K. Simpson, PhD, MSN, CRNP.\u003c\/li\u003e\n\u003cli\u003eHeadquarters: Waconia, Minnesota.\u003c\/li\u003e\n\u003cli\u003eEmployees: \u003cstrong\u003e6\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal cash as of September 30, 2024: \u003cstrong\u003e$142,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSecured up to \u003cstrong\u003e$12.0 million\u003c\/strong\u003e strategic financing commitment from Nant Capital.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Deep, specialized focus in a difficult area builds tacit knowledge that is hard for generalist competitors to match quickly.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePancreatic Cancer Market is projected to grow from an estimated \u003cstrong\u003e$2.7 billion\u003c\/strong\u003e in 2025 to \u003cstrong\u003e$9.7 billion\u003c\/strong\u003e by 2035.\u003c\/li\u003e\n\u003cli\u003eThe market is expected to reach approximately \u003cstrong\u003e$7.4 billion\u003c\/strong\u003e by 2032, with a CAGR of \u003cstrong\u003e13.7%\u003c\/strong\u003e for the period of 2023 – 2032.\u003c\/li\u003e\n\u003cli\u003eThe number of diagnosed incident cases of pancreatic cancer in the 8MM is projected to grow from \u003cstrong\u003e229,166\u003c\/strong\u003e in 2024 to \u003cstrong\u003e283,540\u003c\/strong\u003e by 2034.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePanbela Therapeutics, Inc. (PBLA) - VRIO Analysis: Experienced Scientific and Clinical Leadership\n\u003c\/h2\u003e\n\n\u003cp\u003eThe assessment of Panbela Therapeutics' experienced scientific and clinical leadership through the VRIO framework is detailed below, incorporating relevant financial and operational data points.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe team possesses demonstrable value through direct experience in the pharmaceutical development lifecycle, including regulatory approvals.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe VP of CMC, Quality and Supply Chain has been involved in the approval of drugs including \u003cstrong\u003eSubsys\u003c\/strong\u003e and \u003cstrong\u003eSyndros\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eA Board member has been instrumental in obtaining the approval of \u003cstrong\u003eten drugs\u003c\/strong\u003e, including \u003cstrong\u003ethree\u003c\/strong\u003e since 2004: \u003cstrong\u003eAloxi®\u003c\/strong\u003e, \u003cstrong\u003eDacogen®\u003c\/strong\u003e, and \u003cstrong\u003eLusedra®\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe President and CEO previously served as CEO of Delcath (Nasdaq: DCTH).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe depth of direct, end-to-end approval experience within a small-cap structure is uncommon, as many smaller firms rely on external consultants for such critical functions.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe specific track records and institutional knowledge held by key personnel, such as those with historical success in navigating FDA submissions, are not easily replicated or acquired through standard hiring practices.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe existing leadership structure, featuring a Chief Medical Officer and CEO with relevant executive and clinical development backgrounds, is organized to manage the transition from Phase III data to potential regulatory submission.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Phase III ASPIRE trial for ivospemin continues, with an interim analysis expected in Q1 2025.\u003c\/li\u003e\n\u003cli\u003eFull enrollment for the ASPIRE trial is now anticipated by Q2 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e. Experienced personnel represent a resource that is difficult to build or purchase rapidly, providing a durable, though not entirely inimitable, advantage.\u003c\/p\u003e\n\n\u003ch3\u003eFinance: Update Inputs for Cash Flow Projection and Burn Rate Modeling\u003c\/h3\u003e\n\u003cp\u003eThe following figures from the Q3 2024 period serve as the basis for modeling the cash burn rate and reflecting the impact of the recent financing commitment on the 13-week cash flow projection.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eAmount \/ Detail\u003c\/th\u003e\n\u003cth\u003eReference Period \/ Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2024 Research \u0026amp; Development Spend (Basis for Burn Rate)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Balance (Pre-Nant Capital Funding)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$142,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Nant Capital Commitment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSubsequent to Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNant Capital Tranche A Funded\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.85 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOctober 22, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNant Capital Tranche B Expected Funding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.15 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBy November 15, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Used in Operations\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$12.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eNine months ended September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516228034709,"sku":"pbla-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/pbla-vrio-analysis.png?v=1740203912","url":"https:\/\/dcf-model.com\/fr\/products\/pbla-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}